secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001193125-25-329488
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd receives FDA Fast Track designation for COVID antibody VYD2311
----------------------------------------------------------------------

- FDA Fast Track granted for VYD2311 to prevent COVID in individuals with risk factors for severe disease.
- VYD2311 is an investigational vaccine-alternative monoclonal antibody candidate.
- Phase 3 DECLARATION trial ongoing; top-line data expected mid-2026.
- Fast Track enables priority review and rolling BLA submission if criteria met.
- Total enrollment of 1770 participants in the placebo-controlled trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525329488/0001193125-25-329488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525329488/ivvd-20251223.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-329488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer